KRAS and colorectal carcinoma: Studies have shown that PCSK9 inhibitors (anti-PCSK9 antibodies and PCSK9 translation inhibitors) combined with simvastatin exert a synergistic antitumor effect in APC/KRAS-mutant CRC 60.